QDEL - Quidel more quick diagnosis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis

QDEL 28.14

+5.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ambrym Man who wrote (438)	2/24/1997 11:08:00 AM
From: Robert Busse	of 1693

Two pieces of news relevant to QDEL- Trinity Biotech (TRIBY) just announced they were acquiring Clark Laboratories - which apparently has an OEM agreement w/ Wampole Labs, a division of Carter-Wallace-Wampole is a competitor of Qdel. Check out the TRIBY thread on SI for details. Also, Biota Holding in Australia announced that they were beginning Phase III clinical trials of GG 167, the influenza drug they discovered and subsequently licensed to Glaxo. As most of you probably know, Glaxo, rather than using Biota to develop a rapid diagnostic test to go w/ GG 167, entered into an agreement w/ QDEL to do so and is actually funding QDEL's entire development cost of this project. Biota is apparently trying to develop their own flu diagnostic test along w/ 2 small U.S. comapnies. Anyway, it looks like Phase III testing of GG 167 is proceeding and will hopefully result in an approved drug in the not too distant future (18 months to 2 years hopefully).When their flu test is approved, this will hopefully give QDEL another blockbuster product to sell in a few years to go w/ strep a, H. pylori, and chlamydia. Also, Don't forget about SAFEPLAN!!! BOB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next